3-氧杂-6-氮杂双环[3.1.1]庚烷对甲苯磺酸盐 | 1414860-36-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氧杂-6-氮杂双环[3.1.1]庚烷对甲苯磺酸盐
• 英文名称: 3-oxa-6-azabicyclo[3.1.1]heptane tosylate
• 英文别名: 3-Oxa-6-azabicyclo[3.1.1]heptane 4-methylbenzenesulfonate；4-methylbenzenesulfonic acid;3-oxa-6-azabicyclo[3.1.1]heptane
• CAS: 1414860-36-8
• 化学式: C₅H₉NO*C₇H₈O₃S
• mdl: MFCD28383857
• 分子量: 271.337
• InChiKey: LNDVYWDVZUQJSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.67
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-氧杂-6-氮杂双环[3.1.1]庚烷对甲苯磺酸盐 、 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 [5-Fluoro-2-[4-methyl-3-[[1-(oxan-4-ylmethyl)azetidin-3-yl]methyl]pyrrolo[2,3-c]pyridin-1-yl]phenyl]-(3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methanone
  参考文献：
  名称：

  [EN] SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
  [FR] DÉRIVÉS DE PHÉNYL-1H-PYRROLO [2, 3-C] PYRIDINE SUBSTITUÉS

  摘要：

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

  公开号：

  WO2022253167A1

文献信息

• MCL-1 inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10988451B2

  公开（公告）日：2021-04-27

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开内容一般涉及可用于治疗癌症方法的化合物和药物组合物。
• MCL-1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：EP3793565A1

  公开（公告）日：2021-03-24
• [EN] 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTYRIDINE-3-CARBOXAMIDE UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR CB2 CANNABINOÏDE POUR LE TRAITEMENT DU CANCER
  申请人：[en]TEON THERAPEUTICS, INC.

  公开号：WO2023081730A1

  公开（公告）日：2023-05-11

  The present invention relates to 82 specific 4-hydroxy-2-oxo-1,2- dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid CB2 receptor modulators for the treatment of cancer, e.g. to 6-(4- fluorophenyl)-4-hydroxy-1-(2-(4-methylpiperazin-1-yl)ethyl)-2-oxo-N- (spiro[2.3]hexan-5-yl)-1,2-dihydro-1,8-naphthyridine-3-carboxamide (example 1, compound 1) The present description discloses the synthesis and characterisation of the 82 claimed compounds as well as biological assays thereof.
• [EN] SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PHÉNYL-1H-PYRROLO [2, 3-C] PYRIDINE SUBSTITUÉS
  申请人：[en]JANSSEN PHARMACEUTICA NV

  公开号：WO2022253167A1

  公开（公告）日：2022-12-08

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.